Exelixis, Inc.

NASDAQ:EXEL

Biotechnology

Healthcare
$68.29 +0.65%

+$0.34 today

Market cap
$17.17B
Beta
0.43
P/E (TTM)
16.3
EPS (TTM)
$3.23
52W Low $33.76High $53.93

Volume 1.82M

Average 2.55M

EXEL Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Exelixis, Inc.NASDAQ: EXEL

Financing Cash Flow · Q2 FY2026 · quarter ended Jul 2026

Financing cash flow grows, but more slowly than its trailing trend

Q2 FY2026 financing cash flow of $343.88M (cash outflow) rose 8.7% year over year, behind the +46.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 24.8% from the prior quarter.

Context

  • Financing cash flow amounted to 41.8% of revenue in FY2025, up 12.8 pp from a year earlier.
  • Financing cash flow increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +8.7% toward the trailing-twelve-month pace of +46.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJul 2026
-$343.88M-24.8% QoQ
Last fiscal yearJan 2026
-$969.59M+54.2% YoY
LTMJul 2026
-$1.16B+46.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.7%——
1 year+54.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
(969.59M) USD
Year-over-year change
-54.2%

Financing Cash Flow vs competitors

How EXEL compares with its peers on the latest reported figures

  • EXEL's LTM Jul 2026 financing cash flow of $1.16B is the 4th largest of the 8 companies compared; the peer median is $20.66M.
  • Its year-over-year change of +46.1% is the 3rd highest of 7, against a peer median of +17.1%.
  • Financing cash flow amounts to 47.6% of revenue for EXEL, versus a peer median of 6.7%.
EXEL Competitors Peer median
Financing Cash Flow for EXEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AZNAstraZeneca PLCLTM Sep 2026$5.39B +9.1%+3.4%8.7%
GMABGenmab A/SLTM Jun 2026$4.96B ——120.1%
RVMDRevolution Medicines, Inc.LTM Jun 2026$3.02B +150.2%+27.3%—
EXELExelixis, Inc.LTM Jul 2026$1.16B +46.1%—47.6%
INCYIncyte CorporationLTM Jun 2026$275.24M +867.1%—4.7%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$20.66M -94.1%-57.0%9.5%
HCMHUTCHMED (China) LimitedLTM Jun 2025$11.22M +9.2%—1.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$10.8M +25.0%-54.9%3.6%
Peer median (excluding EXEL) $20.66M+17.1%-25.7%6.7%

Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Jan 2025
FY2025
Jan 2026
Net Income231.06M182.28M207.77M521.27M782.57M
Depreciation & Amortization13.63M20.88M25.72M28.8M29.06M
Deferred Income Tax46.53M(60.36M)(133.21M)(59.46M)126.24M
Stock-Based Compensation119.82M107.57M106.35M93.84M112.98M
Change in Working Capital(39.01M)(12.8M)(13.97M)(13.45M)(191.2M)
Accounts Receivables(122.32M)66.85M(22.62M)(27.95M)(21.4M)
Inventory(13.21M)(11.68M)(12.98M)5.45M12.23M
Accounts Payables55.09M23.36M50.11M(21.89M)(50.15M)
Other Working Capital41.43M(91.32M)(28.48M)30.93M(131.87M)
Other Non-Cash Items28.78M125.04M140.68M128.98M24.62M
Operating Cash Flow400.8M362.61M333.32M699.97M884.27M
Capital Expenditures(64.23M)(138.46M)(162.97M)(66.19M)(39.93M)
Acquisitions (Net)00000
Purchases of Investments(1.36B)(1.45B)(902.47M)(927.91M)(632.5M)
Sales of Investments1.38B1.06B1.04B877.31M1.02B
Other Investing Activities(10M)(110.75M)(122.5M)(37.75M)(31.5M)
Investing Cash Flow(42.88M)(524.41M)(26.96M)(116.78M)350.44M
Debt Repayment00000
Common Stock Issued023.89M33.45M61.85M49.14M
Common Stock Repurchased00(550.38M)(652.03M)(947.51M)
Dividends Paid00000
Other Financing Activities(14.8M)(23.3M)(29.12M)(38.63M)(71.22M)
Financing Cash Flow(14.8M)586K(546.05M)(628.81M)(969.59M)
Effect of Forex Changes00000
Net Change in Cash343.12M(161.21M)(239.68M)(45.62M)265.11M
Free Cash Flow336.58M224.16M170.36M633.79M844.34M

Exelixis, Inc.

NASDAQ:EXEL

Intrinsic Alpha fair value

Locked

Current Price

$68.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.